You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
AstraZeneca
McKesson
Harvard Business School
Express Scripts

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,006,224


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,006,224 protect, and when does it expire?

Patent 9,006,224 protects AFINITOR and is included in one NDA.

This patent has forty-eight patent family members in twenty-four countries.

Summary for Patent: 9,006,224
Title:Neuroendocrine tumor treatment
Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
Inventor(s): Marks; Peter Wayne (Woodbridge, CT), Lebwohl; David (Madison, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:12/094,173
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,006,224
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,006,224

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 AB RX Yes No   Start Trial   Start Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 AB RX Yes No   Start Trial   Start Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 AB RX Yes No   Start Trial   Start Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,006,224

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0523658.3Nov 21, 2005
United Kingdom0601082.1Jan 19, 2006
United Kingdom0602747.8Feb 10, 2006
United Kingdom0607942.0Apr 21, 2006
United Kingdom0609272.0May 10, 2006
PCT Information
PCT FiledNovember 20, 2006PCT Application Number:PCT/EP2006/068656
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/057457

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Johnson and Johnson
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.